Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry ...

Ltd. has identified pyrrole sulfonyl compounds and deuterated derivatives acting as H+/K+-ATPase inhibitors reported to be useful for the treatment of peptic ulcers, Zollinger-Ellison syndrome, ...

a proprietary deuterated DMT program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in ...

a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine ...

PEAK6 Investments LLC lowered its stake in shares of Cybin Inc. (NYSE:CYBN – Free Report) by 97.4% during the third quarter, ...